CRF recently selected two new members to its Board of Directors: Karen G. Krasney, JD, and Frank Litvack, MD. The appointments increase the number of directors to 12. Ms. Krasney is Executive Vice President and General Counsel for Capricor Therapeutics, Inc. Dr. Litvack is Director of Strategy and Alternative Investments at Pura Vida Investments and serves as Executive Chairman of Capricor Therapeutics, Inc.
“We are pleased to add the talent and healthcare insight of these two respected individuals to the CRF Board,” said Jack Lewin, MD, CRF’s President and Chief Executive Officer. “We look forward to the unique perspectives both individuals will provide to CRF’s strategy and operations as we continue to focus on our mission to improve the life of people with cardiovascular disease through research and education.”
Ms. Krasney’s career spans over 35 years, serving as General Counsel for numerous public and private companies engaged in a wide variety of industries. Her extensive background and experience has focused on domestic and international corporate and business law, as well as litigation. She has been involved in medical technology for over twenty years, representing several medical technology companies involved in the development of products for the treatment of cardiovascular disease.
An entrepreneur and accomplished veteran of the healthcare industry, Dr. Litvack has over 25 years of academic and industry experience and also serves on the Health Care Advisory Board of RAND Corporation. He is an Attending Cardiologist at Cedars-Sinai Medical Center and Professor at David Geffen School of Medicine at University of California, Los Angeles. His seminal work with AIS in developing the first FDA-approved excimer laser angioplasty system earned him special recognition from NASA and induction into the Space Technology Hall of Fame.